Effect botulinum toxin (type A) in patellofemoral pain syndrome

Phase 3

Conditions: Patellofemoral pain syndrome.
Patellofemoral disorders, unspecified knee
M22.2X9

Registration Number: IRCT20221202056684N1

Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 52

Inclusion Criteria

Patients aged 18 to 45 years
Clinical diagnosis of PFP syndrome for more than 3 months
Pain rating (out of 10) 4 or more
Failure to respond to treatment despite receiving at least 8 weeks of non-invasive treatment including exercise therapy, exercise therapy and physical therapy

Exclusion Criteria

Presence of knee joint effusion
Presence of any evidence in favor of other tibiofemoral pathologies (patellar tendinopathy, presence of evidence of tibiofemoral osteoarthritis or patellofemoral joint space narrowing or arthrosis on radiographs (Kellgren-Lawrence grade II or higher), meniscal tear, knee instability)
Evidence in favor of spinal canal stenosis, lumbar radiculopathy, neuropathy and lower limb neuronal damage
Any intra-articular injection of the knee in the last 6 months (including hyaluronic acid, ozone or steroids)
Body mass index > 35
Previous knee surgery
Evidence of injury or inflammatory arthritis of the hip joint
Allergy to BoNT-A
Pregnancy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The amount of pain assessed by Visual Analogue Scale score. Timepoint: The beginning of the study and 2 months after the injection. Method of measurement: Visual Analogue Scale.;Examination of knee function using the Anterior Knee Pain Scale. Timepoint: The beginning of the study and 2 months after the injection. Method of measurement: Anterior Knee Pain Scale.;Examination of knee function using the Knee injury and Osteoarthritis Outcome Score-Patellofemoral subscale. Timepoint: The beginning of the study and 2 months after the injection. Method of measurement: Knee injury and Osteoarthritis Outcome Score-Patellofemoral subscale.

Secondary Outcome Measures